Filing summary
Entity and period: The supplied filing is StemCells, Inc.’s Form 10-K for the fiscal year ended December 31, 2014, not a Microbot Medical filing. It includes unaudited fourth-quarter results. Verify the issuer identity before relying on this summary.
Business context and reporting period
StemCells was a clinical-stage biotechnology company developing HuCNS-SC human neural stem cells for central nervous system conditions. Its main clinical programs addressed chronic spinal cord injury and dry age-related macular degeneration (AMD); it had no approved therapeutic products and depended on external financing. In the fourth quarter, it sold its SC Proven reagent and cell-culture business and wound down its U.K. subsidiary operations, reporting these activities as discontinued operations.
Key financial metrics
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Continuing-operations revenue | $1.01 million | $0.17 million |
| Research and development expense | $21.50 million | $19.37 million |
| General and administrative expense | $10.42 million | $8.83 million |
| Operating loss | $30.91 million | $28.09 million |
| Net loss, including discontinued operations | $32.74 million | $26.44 million |
| Basic and diluted net loss per share | $0.53 | $0.61 |
| Net cash used in operating activities | $27.35 million | $23.32 million |
| Cash and cash equivalents at year-end | $24.99 million | $30.59 million |
| Total assets | $32.43 million | $41.56 million |
| Total liabilities | $26.56 million | $26.60 million |
| Stockholders’ equity | $5.87 million | $14.95 million |
- Revenue was primarily from licensing fees and milestones, not therapeutic product sales. The year-over-year increase reflected a roughly $500,000 ReNeuron milestone and $400,000 in Takara Bio licensing fees associated with the SC Proven divestiture.
- Operating expenses rose 13%; R&D expense increased 11%, largely due to clinical trials and expanded development capabilities. No operating margin is meaningful for this loss-making, pre-commercial business.
- Other non-current debt included the Silicon Valley Bank loan and CIRM financing. The reported loan payable, net of discount, was $15.02 million, including $9.60 million related to CIRM. The SVB loan carried 6% stated interest, security over substantially all assets except intellectual property, and a $1 million final fee.
- Cash declined by $5.60 million during 2014 despite $22.20 million in net financing cash flow. July’s equity-and-warrant offering raised $20 million gross. Outstanding common shares increased to 68.73 million from 55.14 million at year-end 2013.
- The filing reports no cash dividends. The year-end share price was $0.94, below Nasdaq’s stated $1.00 minimum bid-price requirement.
Material changes versus the prior period
- Net loss increased by $6.30 million, while operating cash use increased by $4.03 million.
- Continuing revenue rose substantially from a low 2013 base, but remained small relative to R&D and administrative spending.
- The company recorded $2.44 million of impairments: $1.91 million of goodwill and $530,000 related to the Transgenic Rat Program intangible asset.
- A $2.42 million non-cash gain from the change in fair value of warrant liabilities partially offset expenses; warrant-liability valuation changes also made reported results more variable.
- After findings in its Alzheimer’s preclinical program failed to meet CIRM’s funding criteria, StemCells wound down the study. CIRM forgave approximately $8.92 million of principal and $243,000 of accrued interest under the loan terms; the company repaid approximately $679,000 in February 2015. The filing says accounting derecognition required a legal release.
- The company completed the SC Proven sale and U.K. wind-down, recording a $111,000 loss on disposal. Discontinued operations reported a $481,000 net loss for 2014.
Outlook, risks and unusual items
- Management expected substantial additional operating losses and stated that profitability was not expected within the next several years. It warned that existing capital resources might not fund operations beyond the next twelve months and that future financing might not be available on acceptable terms.
- Planned development included a randomized, controlled Phase II study for cervical spinal cord injury, targeting up to 52 subjects, and a follow-on randomized, controlled Phase II AMD study planned for 2015. Final results from the earlier spinal cord injury and AMD trials were expected around mid-2015. These are forward-looking statements, not assured outcomes.
- Interim trial observations included sensory-function gains in six of 12 chronic thoracic spinal cord injury subjects and, in four initial AMD cohort subjects, reported reductions in geographic-atrophy progression versus control eye and expected natural history. These were preliminary findings; the filing notes the need for further testing to establish efficacy.
- Key risks include dependence on one principal cell platform and early-stage clinical programs; clinical, manufacturing and regulatory failure or delay; need for substantial additional capital; dilution; uncertainty about reimbursement and commercial acceptance; and patent litigation. A trial concerning whether StemCells had legal standing in its Neuralstem patent litigation was underway, with a ruling expected in the first half of 2015.
- Operating lease commitments totaled $16.22 million; contractual cash obligations, including leases and debt, totaled $22.70 million at year-end. Auditors issued an unqualified opinion on the financial statements and internal control over financial reporting; management also concluded controls were effective.
Important facts for investors to verify
- Confirm that the intended filing is StemCells, Inc.’s 2014 Form 10-K; the request names Microbot Medical, a different company.
- Review subsequent filings for actual cash runway, financing, debt repayment and the status of CIRM’s legal release and loan accounting.
- Check whether the planned AMD and cervical spinal cord injury studies proceeded, and assess complete controlled-trial results rather than interim observations.
- Verify Nasdaq listing compliance, subsequent share issuance, warrant exercises and potential dilution.
- Review the Neuralstem litigation outcome and the remaining term and enforceability of key patents.